Galecto Inc (GLTO) Stock Price, Quote & News

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 52 10

Website: galecto.com

Address:

Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark

ChaseDeluca Dec. 4 at 10:50 PM

$CRML $SMX $BBAI $GLTO watch DEVS, todays news is massive! This can fly over night, SMX vibes. Tiny float, huge news, highly shorted. ......................

0 · Reply

AvengerTrader Dec. 4 at 10:04 PM

What is happening to ticker SNSE now?! Looks like they are going to SQUEEZE ticker SNSE up next .. SNSE is breaking out like crazy.. Its insane what's going on in this market.. Looks like all eyes are going to SNSE now.. watching $MAGH $GLTO $GSAT $BYND now

0 · Reply

ProfitsBee Dec. 4 at 8:37 PM

Do NOT chase tickers up 1000%. If you want to be earlier on a $SMX type of ticker, make sure to check out $SNSE SNSE is bouncing hard off its bottom and has only 520k shares outstanding. I've seen a lot of people chasing $BYND $GLTO $MTC after they already ran SNSE could be a top runner very soon, It's starting its uptrend up now Starting to breakout - looks like people are moving in to SNSE

0 · Reply

Pinceconez_Tradings Dec. 4 at 2:12 AM

Banked up $8.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He calls them early before anyone else. Love adding before the runs✅ Breakout watch -> $GLTO $DVLT $MAGH $TERN

0 · Reply

theoneis Dec. 3 at 1:52 AM

Glto

0 · Reply

Paraboljoker Dec. 3 at 12:47 AM

$PMAX $PMAX 🇭🇰10001000% like $GLTO $MTC $HKD $SMX did??

0 · Reply

Bigwinner75 Dec. 1 at 4:00 PM

$GLTO keep watching 20 bucks to key level

0 · Reply

Bigwinner75 Dec. 1 at 3:55 PM

$GLTO i will be short this pos again once i cover my $SMX

1 · Reply

notreload_ai Dec. 1 at 1:31 PM

Guggenheim initiates coverage on $GLTO with a Buy rating and $32 target, citing strong potential for its newly acquired drug DMR-001 and solid funding through 2029. https://notreload.xyz/galecto-gains-momentum-with-new-drug-class-and-strong-funding/

0 · Reply

JarvisFlow Dec. 1 at 12:49 PM

Guggenheim has updated their rating for Galecto ( $GLTO ) to Buy with a price target of 32.

0 · Reply

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

MOVE

Nov 10, 2025, 11:47 AM EST - 24 days ago

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Nov 10, 2025, 7:00 AM EST - 24 days ago

Galecto Announces Acquisition of Damora Therapeutics

Nov 6, 2025, 4:30 PM EST - 4 weeks ago

Galecto Reports Third Quarter 2025 Operating and Financial Results

Oct 7, 2025, 1:05 PM EDT - 2 months ago

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 10:27 AM EDT - 2 months ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Aug 5, 2025, 4:15 PM EDT - 4 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 7 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Mar 19, 2025, 4:45 PM EDT - 9 months ago

Galecto Reports Full-Year 2024 Financial Results

Feb 6, 2025, 8:00 AM EST - 10 months ago

Galecto to Participate in Upcoming Investor Conferences

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 17, 2023, 4:01 PM EDT - 2 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Apr 28, 2023, 8:00 AM EDT - 2 years ago

Galecto Reports First Quarter Operating and Financial Results

Apr 18, 2023, 7:01 PM EDT - 2 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 13, 2023, 8:30 AM EDT - 2 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Mar 9, 2023, 7:00 AM EST - 2 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 2, 2023, 4:05 PM EST - 3 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 1, 2023, 8:00 AM EST - 3 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

May 31, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at Jefferies Healthcare Conference

May 26, 2022, 8:30 AM EDT - 3 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

Apr 26, 2022, 8:30 AM EDT - 3 years ago

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Mar 29, 2022, 8:30 AM EDT - 4 years ago

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Feb 17, 2022, 5:00 PM EST - 4 years ago

Galecto Reports Financial Results for the Year Ended December 31, 2021

ChaseDeluca Dec. 4 at 10:50 PM

$CRML $SMX $BBAI $GLTO watch DEVS, todays news is massive! This can fly over night, SMX vibes. Tiny float, huge news, highly shorted. ......................

0 · Reply

AvengerTrader Dec. 4 at 10:04 PM

0 · Reply

ProfitsBee Dec. 4 at 8:37 PM

0 · Reply

Pinceconez_Tradings Dec. 4 at 2:12 AM

0 · Reply

theoneis Dec. 3 at 1:52 AM

Glto

0 · Reply

Paraboljoker Dec. 3 at 12:47 AM

$PMAX $PMAX 🇭🇰10001000% like $GLTO $MTC $HKD $SMX did??

0 · Reply

Bigwinner75 Dec. 1 at 4:00 PM

$GLTO keep watching 20 bucks to key level

0 · Reply

Bigwinner75 Dec. 1 at 3:55 PM

$GLTO i will be short this pos again once i cover my $SMX

1 · Reply

notreload_ai Dec. 1 at 1:31 PM

0 · Reply

JarvisFlow Dec. 1 at 12:49 PM

Guggenheim has updated their rating for Galecto ( $GLTO ) to Buy with a price target of 32.

0 · Reply

daytrader0 Nov. 28 at 4:24 PM

$GLTO f this manipulated pos .. should be down alot more.. i covered for a small gain and moving on... low as* volume in pre market and they move the bid 2 points ... then it drips n drips n same sh*t show story.. think it still will fall alot more but i'm tired of wiating in this slow name .. better things to trade out there.. scam street and crooked mms can have it at in this name.. still a 5 bucks name at best..

0 · Reply

LuckSociety Nov. 28 at 12:47 PM

Today’s picks: $KSS $BYND $GLTO $TNXP

0 · Reply

daytrader0 Nov. 26 at 5:04 PM

$GLTO again if it weren't for the manipulation of pre market this would be down 1+ easily today.. no biz being here.. n for monday again they will put the ask at 19 for no reason and do a 50 share sell/buy at that point to make a fake bid/ask n try to stick at those insane numbers.. f*ck this scam and this scam name and crooked mms.

0 · Reply

daytrader0 Nov. 26 at 3:28 PM

$GLTO every pre market they manipulate the bid/ask to put it 2+ higher than previous close n it still doesn't stick cuz nobodys buying.. maybe some shorts cover but that's about it.. then it comes back to reality n drips lower ... this should be already at 10 or lower if it weren't for the 5000 shares trades in pre market/after market to fix the bid/ask at higher than it should be trading. that's the reason for this dead action else it would be lower n lower and bag holders would be exiting.

0 · Reply

daytrader0 Nov. 26 at 3:03 PM

$GLTO side way side way .. til the next leg down.. rinse n repeat.. til we go back to 3s where it came from.. then they do another reverse split.. announce one more "new" fluff piece... then pump and dump cycle restarts... am i missing something here lol

0 · Reply

CM20 Nov. 24 at 5:43 PM

$GLTO covered 3/4 of my position today. Made lots of mullah$

0 · Reply

ryerson1 Nov. 22 at 8:43 PM

$GLTO Let ride this up again ,

1 · Reply

trader949 Nov. 21 at 6:03 PM

$GLTO nothing but air holding this.. ran on fluff and pumpers long gone only stubborn retail left as bag holders n mms trying to trap more suckers holding it up here... look at every single pump in this scam name.. months of bleed down even further below where it was pumped.. let it get to low lows then another reverse split or some pr piece to do another pump.. and on and on and on.. this market full of bubbles to burst.

0 · Reply

Bigwinner75 Nov. 21 at 12:39 AM

$GLTO I cover way too early. 19.55. Didn’t even make money. Just break even. I am not good at shorting

1 · Reply

P4jt Nov. 20 at 5:02 PM

$GLTO LIKE TAKING CANDY FROM A BABY……CHEERSP4

0 · Reply

Bigwinner75 Nov. 20 at 6:08 AM

$GLTO it doesn’t have a solid support at 9 dollars. Will be extremely hard. Stocks is like a building. You need foundation. Can’t build in the sky

1 · Reply

ryerson1 Nov. 19 at 10:42 PM

$GLTO This is ready to run again , should run to 35.00 Next stop

2 · Reply

Market Cap	25.67M
Revenue (ttm)	0.00
Net Income (ttm)	-21.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	246,100
Avg Vol	3,346,660
Day's Range	N/A - N/A
Shares Out	1.33M
Stochastic %K	99%
Beta	1.40
Analysts	Sell
Price Target	$19.00